RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

RxSight (RXST) reported a Q2 2025 loss of $0.08 per share, outperforming the Zacks consensus estimate of a $0.10 loss, and revenues of $33.64 million, slightly exceeding expectations despite a year-over-year decline. Despite these beats, the stock has significantly underperformed the broader market, down 78% year-to-date. The company currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revisions and operates within a lower-ranked industry, indicating potential continued near-term underperformance, with future price action largely contingent on management's earnings call commentary.

Analysis

RxSight, Inc. (RXST) reported a Q2 loss of $0.08 per share, which, while 20% better than the Zacks Consensus Estimate, marks a significant deterioration from the break-even earnings per share recorded a year ago. Similarly, quarterly revenue of $33.64 million, though marginally beating estimates by 0.11%, represents a year-over-year decline from $34.89 million. This fundamental weakness is reflected in the stock's severe market underperformance, with shares down 78% year-to-date against the S&P 500's 7.9% gain. The forward-looking consensus estimates suggest continued challenges, with projections for a wider loss of $0.20 per share on lower sequential revenues of $29.04 million in the coming quarter. Compounding these negative indicators, the stock carries a Zacks Rank #4 (Sell) due to a pre-existing unfavorable trend in earnings estimate revisions, and operates within the Medical - Instruments industry, which is ranked in the bottom 41% of all Zacks industries, suggesting broad sector headwinds.

Key Decisions for Investors

• Investors should view the headline earnings beat with significant caution, as it is overshadowed by the year-over-year declines in both revenue and profitability and does not negate the underlying negative operational trend.
• The primary focus must be on management's forward-looking commentary from the earnings call, which will be the critical catalyst determining if there is any basis for a change in the stock's severely negative trajectory.
• Given the stock's Zacks #4 (Sell) rating and the unfavorable industry ranking, maintaining or initiating a long position carries a high degree of risk, and continued market underperformance should be expected in the near term.
• Closely monitor any revisions to consensus earnings estimates in the coming days, as a failure to see positive revisions post-earnings would reinforce the existing bearish thesis.